North Star Investment Management Corp. decreased its stake in Shire PLC (NASDAQ:SHPG) by 13.0% during the third quarter, Holdings Channel reports. The firm owned 697 shares of the biopharmaceutical company’s stock after selling 104 shares during the period. North Star Investment Management Corp.’s holdings in Shire PLC were worth $135,000 as of its most recent filing with the SEC.
A number of other large investors have also bought and sold shares of SHPG. Quadrant Capital Group LLC raised its position in Shire PLC by 157.6% in the second quarter. Quadrant Capital Group LLC now owns 608 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 372 shares during the period. Canal Insurance CO bought a new position in Shire PLC during the second quarter worth about $102,000. FTB Advisors Inc. raised its position in Shire PLC by 3.1% in the second quarter. FTB Advisors Inc. now owns 600 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 18 shares during the period. Duncker Streett & Co. Inc. bought a new position in Shire PLC during the second quarter worth about $111,000. Finally, Ropes Wealth Advisors LLC bought a new position in Shire PLC during the second quarter worth about $114,000. 24.49% of the stock is owned by institutional investors.
Shares of Shire PLC (NASDAQ:SHPG) traded up 0.78% during midday trading on Friday, hitting $175.23. The stock had a trading volume of 908,697 shares. The firm has a 50 day moving average of $0.00 and a 200-day moving average of $0.00. Shire PLC has a one year low of $147.60 and a one year high of $215.05.
Shire PLC (NASDAQ:SHPG) last issued its earnings results on Tuesday, November 1st. The biopharmaceutical company reported $3.17 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $3.21 by $0.04. Shire PLC had a return on equity of 14.81% and a net margin of 1.62%. The business earned $3.45 billion during the quarter, compared to the consensus estimate of $3.57 billion. During the same period in the prior year, the business earned $3.24 EPS. The business’s revenue was up 108.6% on a year-over-year basis. On average, analysts anticipate that Shire PLC will post $12.93 earnings per share for the current fiscal year.
A number of research firms recently issued reports on SHPG. Piper Jaffray Cos. set a $201.00 target price on Shire PLC and gave the company a “hold” rating in a report on Saturday, October 1st. Leerink Swann reaffirmed a “buy” rating on shares of Shire PLC in a report on Saturday, October 1st. Citigroup Inc. reaffirmed a “buy” rating on shares of Shire PLC in a report on Wednesday, August 3rd. RBC Capital Markets reaffirmed an “outperform” rating on shares of Shire PLC in a report on Wednesday, August 3rd. Finally, Zacks Investment Research raised Shire PLC from a “sell” rating to a “hold” rating in a report on Thursday, August 4th. Four analysts have rated the stock with a hold rating and twenty-three have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $222.06.
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.